Twenty-eight months progression-free survival after pyrotinib therapy for HER2-positive recurrent ovarian clear cell carcinoma: a case report

Jing Wu, Qian Li, Rongyuan Zhuang et al.|Annals of Translational Medicine|2022

Cited by 7